Journal of Stroke & Cerebrovascular Diseases
Volume 19, Issue 1 , Pages 40-48 , January 2010

Time of Day, Outcome, and Response to Thrombolytic Therapy: The National Institute of Neurological Disorders and Stroke Recombinant Tissue Plasminogen Activator Stroke Trial Experience

  • Denise H. Rhoney, PharmD

      Affiliations

    • Department of Pharmacy Practice, Wayne State University, Detroit, Michigan
    • Department of Neurology, Wayne State University, Detroit, Michigan
    • Corresponding Author InformationAddress correspondence to Denise H. Rhoney, PharmD, Departments of Pharmacy Practice and Neurology, Wayne State University, 259 Mack Ave, Detroit, MI 48201.
    • ,
  • William M. Coplin, MD

      Affiliations

    • Department of Neurology, Wayne State University, Detroit, Michigan
    • Department of Neurological Surgery, Wayne State University, Detroit, Michigan
    • ,
  • Yan Lin, PhD, MS

      Affiliations

    • Department of Biostatistics, Medical University of South Carolina, Charleston
    • Department of Neurology, Emory University School of Medicine, Atlanta, Georgia
    • ,
  • Michael Frankel, MD

      Affiliations

    • Department of Neurosciences, University of California, San Diego
    • ,
  • Patrick D. Lyden, MD

      Affiliations

    • Department of Neurology, The Mount Sinai School of Medicine, New York, New York
    • ,
  • Steven R. Levine, MD

      Affiliations

    • Mount Sinai Stroke Center, The Mount Sinai School of Medicine, New York, New York

Received 5 January 2009 ,Revised 4 March 2009 ,Accepted 9 March 2009.

References 

  1. Marsh EE, Biller J, Adams HP, et al. Circadian variation in onset of acute ischemic stroke. Arch Neurol. 1990;47:1178–1180
  2. Marler JR, Price TR, Clark GL, et al. Morning increase in onset of ischemic stroke. Stroke. 1989;20:473–476
  3. Kurnik PB. Circadian variation in the efficacy of tissue-type plasminogen activator. Circulation. 1995;91:1341–1346
  4. Becker RC, Corrao JM, Baker SP, et al. Circadian variation in thrombolytic response to recombinant tissue-type plasminogen activator in acute myocardial infarction. J Appl Cardiol. 1988;3:213–221
  5. Fujita M, Araie E, Yamanishi K, et al. Circadian variation in the success rate of intracoronary thrombolysis for acute myocardial infarction. Am J Cardiol. 1993;71:1369–1371
  6. Goldhammer E, Kharash L, Abinader EG. Circadian fluctuations in the efficacy of thrombolysis with streptokinase. Postgrad Med J. 1999;75:667–671
  7. Kono T, Morita H, Nishina T, et al. Circadian variations of onset of acute myocardial infarction and efficacy of thrombolytic therapy. J Am Coll Cardiol. 1996;27:774–778
  8. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med. 1995;333:1581–1587
  9. van Swieten JC, Koudstaal PJ, Visser MC, et al. Interobserver agreement for the assessment of handicap in stroke patients. Stroke. 1988;19:604–607
  10. Jennett B, Bond M. Assessment of outcome after severe brain damage. Lancet. 1975;1:480–484
  11. Chaturvedi S, Adams HP, Woolson RF. Circadian variation in ischemic stroke subtypes. Stroke. 1999;30:1792–1795
  12. Argentino C, Toni D, Rasura M, et al. Circadian variation in the frequency of ischemic stroke. Stroke. 1990;21:387–389
  13. Gallerani M, Manfredini R, Ricci L, et al. Chronobiological aspects of acute cerebrovascular diseases. Acta Neurol Scand. 1993;87:482–487
  14. Marshall J. Diurnal variation in occurrence of strokes. Stroke. 1977;8:230–231
  15. Tilley BC, Marler J, Geller NL, et al. Use of a global test for multiple outcomes in stroke trials with application to the National Institute of Neurological Disorders and Stroke t-PA stroke trial. Stroke. 1996;27:2136–2142
  16. The National Institute of Neurological Disorders and Stroke (NINDS) rt-PA Stroke Study Group. Effect of intravenous recombinant tissue plasminogen activator on ischemic stroke lesion size measured by computed tomography. Stroke. 2000;31:2912–2919
  17. Marler JR, Tilley BC, Lu M, et al. Early stroke treatment associated with better outcome: The NINDS rt-PA stroke study. Neurology. 2000;55:1649–1655
  18. Tofler GH, Brezinski D, Schafer AI, et al. Concurrent morning increase in platelet aggregability and the risk of myocardial infarction and sudden cardiac death. N Engl J Med. 1987;316:1514–1518
  19. Petralito A, Mangiafico RA, Gibiino S, et al. Daily modifications of plasma fibrinogen platelets aggregation, Howell's time, PTT, TT, and antithrombin II in normal subjects and in patients with vascular disease. Chronobiologia. 1982;9:195–201
  20. Ehrly AM, Jung G. Circadian rhythm of human blood viscosity. Biorheology. 1973;10:577–583
  21. Weitzman ED, Fukushima D, Nogeire C, et al. Twenty-four hour pattern of the episodic secretion of cortisol in normal subjects. J Clin Endocrinol Metab. 1971;33:14–22
  22. Turton MB, Deegan T. Circadian variations of plasma catecholamine, cortisol and immunoreactive insulin concentrations in supine subjects. Clin Chim Acta. 1974;55:389–397
  23. Bremner WF, Sothern RB, Kanabrocki EL, et al. Relation between circadian patterns in levels of circulating lipoprotein(a), fibrinogen, platelets, and related lipid variables in men. Am Heart J. 2000;139:164–173
  24. Decousus HA, Croze M, Levi FA, et al. Circadian changes in anticoagulant effect of heparin infused at a constant rate. Br Med J. 1985;290:341–344
  25. Angleton P, Chandler WL, Schmer G. Diurnal variation of tissue-type plasminogen activator and its rapid inhibitor (PAI-1). Circulation. 1989;79:101–106
  26. Grimaudo V, Hauert J, Bachmann F, et al. Diurnal variation of the fibrinolytic system. Thromb Haemost. 1988;59:495–499
  27. Rosing DR, Redwood DR, Brakman P, et al. Impairment of the diurnal fibrinolytic response in man: Effects of aging, type IV hyperlipoproteinemia, and coronary artery disease. Circ Res. 1973;32:752–758
  28. Molina CA, Ribo M, Romero F, et al. Hemodynamic changes in the basilar artery following stenting. Neurology. 2004;62:1398
  29. Rubiera M, Ribo M, Delgado-Mederos R, et al. Tandem internal carotid artery/middle cerebral artery occlusion: An independent predictor of poor outcome after systemic thrombolysis. Stroke. 2006;37:2301–2305
  30. Arenillas JF, Alvarez-Sabin J, Molina CA, et al. Progression of symptomatic intracranial large artery atherosclerosis is associated with a proinflammatory state and impaired fibrinolysis. Stroke. 2008;39:1456–1463
  31. Anand S, Diamond SL. Computer simulation of systemic circulation and clot lysis dynamics during thrombolytic therapy that accounts for inner clot transport and reaction. Circulation. 1996;94:763–774
  32. Saqqur M, Uchino K, Demchuk AM, et al. Site of arterial occlusion identified by transcranial Doppler predicts the response to intravenous thrombolysis for stroke. Stroke. 2007;38:948–954
  33. Casetta I, Granieri E, Portaluppi F, et al. Circadian variability in hemorrhagic stroke. JAMA. 2002;287:1266–1267
  34. Sloan MA, Price TR, Foulkes MA, et al. Circadian rhythmicity of stroke onset: Intracerebral and subarachnoid hemorrhage. Stroke. 1992;23:1420–1426
  35. Gallerani M, Trappella G, Manfredini R, et al. Acute intracerebral hemorrhage: Circadian and circannual patterns of onset. Acta Neurol Scand. 1994;89:280–286
  36. Nyquist PA, Brown RD, Wiebers DO, et al. Circadian and seasonal occurrence of subarachnoid and intracerebral hemorrhage. Neurology. 2001;56:190–193
  37. Frankel MR, Morgenstern LB, Kwiatkowski T, et al. Predicting prognosis after stroke: A placebo group analysis from the National Institute of Neurological Disorders and Stroke rt-PA stroke trial. Neurology. 2000;55:952–959

 Supported by the National Institute of Neurological Disorders and Stroke (N01-NS-02383, N01-NS-02374, N01-NS-02377, N01-NS-02381, N01-NS-02379, N01-NS-02373, N01-NS-02378, N01-NS-02376, N01-NS-02380, K24N543992, and R01-NS-38905).

PII: S1052-3057(09)00064-0

doi: 10.1016/j.jstrokecerebrovasdis.2009.03.006

Journal of Stroke & Cerebrovascular Diseases
Volume 19, Issue 1 , Pages 40-48 , January 2010

Article Tools

* Image Usage & Resolution